Search

Your search keyword '"Calleja, Miguel Angel"' showing total 27 results
Start Over Author "Calleja, Miguel Angel"
27 results on '"Calleja, Miguel Angel"'

5. Liquid chromatography tandem mass spectrometric determination of triterpenes in human fluids: Evaluation of markers of dietary intake of olive oil and metabolic disposition of oleanolic acid and maslinic acid in humans

Author

Pozo, Oscar J., Pujadas, Mitona, Gleeson, Sarah Biel, Mesa-García, Maria Dolores, Pastor, Antoni, Kotronoulas, Aristotelis, Fitó, Montserrat, Covas, Maria-Isabel, Navarro, José Ramón Fernández, Espejo, Juan Antonio, Sanchez-Rodriguez, Estefania, Marchal, Rosa, Calleja, Miguel Angel, and de la Torre, Rafael

Published
2017
Full Text
View/download PDF

6. Approaches for a hepatitis C-free city: preliminary results

Author

Luque Gonzalez, Maria Angelica, primary, Sánchez, Yolanda, additional, Romero, Carmen Lara, additional, Lucena, Ana, additional, Ampuero, Javier, additional, Atienza, Francisco, additional, Marquez, Valentin, additional, Eduardo, Briones, additional, Ufano Lopez, Rosa Maria, additional, Martinez, Fernando, additional, Lozano Domínguez, María Carmen, additional, Corrales, Tinidad Desongles, additional, Martinez, Lola, additional, Valero, Rocio, additional, Torralbo, Manuel, additional, García, Diego, additional, Melero, Maria Jose, additional, Crespillo, Lutgarda Conde, additional, Barba, Minerva Blazquez, additional, Calleja, Miguel Angel, additional, Garcia-Samaniego Rey, Francisco Javier, additional, Fernández-Cuenca, Felipe, additional, Carmona, Isabel, additional, Padrones, Susana, additional, Sanchez, Antonio, additional, and Gomez, Manuel Romero, additional

Published
2022
Full Text
View/download PDF

10. Budget impact analysis of bevacizumab biosimilars

Author

Calleja, Miguel Angel, Albanell Mestres, Joan, Aranda, Enrique, García-Foncillas, Jesús, Feliu, Anna, Rivera, Fernando, Oyagüez, Itziar, Salinas-Ortega, Laura, and Soto Alvarez, Javier

Subjects
Health care economics and organizations, Public health, Medical oncology, Economics, Antineoplastic agents, Pharmaceutical
Abstract

Data de publicació electrònica: 22-12-2021 Objective: to assess the economic impact of introducing biosimilars of bevacizumab for the management of cancer patients receiving systemic bevacizumab in the National Health System (SNHS) of Spain. Methods: a 3-year budget impact analysis model was adapted to estimate the cost of introducing biosimilars of bevacizumab in the SNHS for the adult population who were candidates to receive treatment with bevacizumab. Values for the estimation of the population were obtained from the literature and were validated by an expert panel. In this analysis only pharmaceutical costs (€, year 2021) obtained from official databases were considered. A sensitivity analysis was performed to examine the robustness of the model. Results: the introduction of bevacizumab biosimilars would generate an annual cost saving of €11 558 268 (-5.1%) for the first year with a penetration share of biosimilars from 30.0%, €29 126 373 (-8.5%) for the second year with a share of 50.0% and €52 361 778 (-13.6%) for the third year with a share of 80.0%. The total pharmaceutical costs of the scenario without biosimilars are €227 033 352 for the first year, €342 663 209 for the second year and €385 013 076 for the third year. In contrast, the pharmaceutical costs of the scenario with bevacizumab biosimilars are €215 475 084, €313 536 836 and €332 651 297 for years 1, 2 and 3, respectively. Conclusions: the introduction of biosimilars in the Spanish Health System would generate saving costs in the pharmacological budget to boost biological drugs from the first year.

Published
2021

11. FRI329 - Approaches for a hepatitis C-free city: preliminary results

Author

Luque Gonzalez, Maria Angelica, Sánchez, Yolanda, Romero, Carmen Lara, Lucena, Ana, Ampuero, Javier, Atienza, Francisco, Marquez, Valentin, Eduardo, Briones, Ufano Lopez, Rosa Maria, Martinez, Fernando, Lozano Domínguez, María Carmen, Corrales, Tinidad Desongles, Martinez, Lola, Valero, Rocio, Torralbo, Manuel, García, Diego, Melero, Maria Jose, Crespillo, Lutgarda Conde, Barba, Minerva Blazquez, Calleja, Miguel Angel, Garcia-Samaniego Rey, Francisco Javier, Fernández-Cuenca, Felipe, Carmona, Isabel, Padrones, Susana, Sanchez, Antonio, and Gomez, Manuel Romero

Published
2022
Full Text
View/download PDF

13. Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease

Author

Guerra Veloz, María Fernanda, primary, Argüelles-Arias, Federico, additional, Castro Laria, Luisa, additional, Maldonado Pérez, Belén, additional, Benítez Roldan, Antonio, additional, Perea Amarillo, Raúl, additional, Merino Bohórquez, Vicente, additional, Calleja, Miguel Angel, additional, Caunedo Álvarez, Ángel, additional, and Vilches Arenas, Ángel, additional

Published
2018
Full Text
View/download PDF

15. Adherence to oral therapies in metastatic castration resistance (m CRPC) prostate cancer patients: The ADOPTA study.

Author

De la LLave, Sandra, primary, Carpeño, Laura, additional, Benedetti, Johanna, additional, Carles, Joan, additional, Puente, Javier, additional, Pinto, Alvaro, additional, Grande, Enrique, additional, Carballido, Joaquin, additional, Lorente, David, additional, González-Billalabeitia, Enrique, additional, Morales, Rafael, additional, Gajate, Pablo, additional, Alfonso, Rosario, additional, Pérez-Valderrama, Begoña, additional, Sanchez Gastaldo, Amparo, additional, Fernandez, Fatima, additional, Calleja, Miguel Angel, additional, and Duran, Ignacio, additional

Published
2017
Full Text
View/download PDF

16. The NUTRAOLEOUM Study, a randomized controlled trial, for achieving nutritional added value for olive oils

Author

Biel, Sara, primary, Mesa, Maria-Dolores, additional, de la Torre, Rafael, additional, Espejo, Juan-Antonio, additional, Fernández-Navarro, Jose-Ramón, additional, Fitó, Montserrat, additional, Sánchez-Rodriguez, Estefanía, additional, Rosa, Carmen, additional, Marchal, Rosa, additional, Alche, Juan de Dios, additional, Expósito, Manuela, additional, Brenes, Manuel, additional, Gandul, Beatriz, additional, Calleja, Miguel Angel, additional, and Covas, María-Isabel, additional

Published
2016
Full Text
View/download PDF

25. The Chemotherapeutic Drug 5-Fluorouracil Promotes PKR-Mediated Apoptosis in a p53- Independent Manner in Colon and Breast Cancer Cells

Author

García, María Angel, primary, Carrasco, Esther, additional, Aguilera, Margarita, additional, Alvarez, Pablo, additional, Rivas, Carmen, additional, Campos, Joaquin María, additional, Prados, Jose Carlos, additional, Calleja, Miguel Angel, additional, Esteban, Mariano, additional, Marchal, Juan Antonio, additional, and Aránega, Antonia, additional

Published
2011
Full Text
View/download PDF

27. Pharmacogenetic polymorphisms contributing to toxicity induced by methotrexate in the southern Spanish population with rheumatoid arthritis.

Author

Plaza-Plaza JC, Aguilera M, Cañadas-Garre M, Chemello C, González-Utrilla A, Faus Dader MJ, and Calleja MA

Subjects
Adult, Aged, Alleles, Antirheumatic Agents therapeutic use, Female, Gene Frequency, Genotype, Humans, Male, Methotrexate therapeutic use, Middle Aged, Spain, Antirheumatic Agents adverse effects, Arthritis, Rheumatoid drug therapy, Arthritis, Rheumatoid genetics, Methotrexate adverse effects, Methylenetetrahydrofolate Reductase (NADPH2) genetics, Polymorphism, Single Nucleotide, White People
Abstract

Abstract Rheumatoid arthritis (RA) is a common illness of global significance for public health. Methotrexate (MTX) is the most broadly used disease-modifying antirheumatic drug for the treatment of RA, but it displays marked person-to-person variation in its propensity for toxicity. Several studies have suggested that polymorphisms in methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C, reduced folate carrier (RFC1) G80A, and ABCB1 C3435T, could be related to methotrexate toxicity. This prospective study examined the different frequencies of MTHFR, RFC1, and ABCB1 pharmacogenetic variations between patients who have RA and those without RA. We also sought to assess the association between these polymorphisms and MTX toxicity. Four single-nucleotide polymorphisms (SNPs) were genotyped: C677T and A1298C from MTHFR, G80A from RFC1, and C3435T from ABCB1. The efficacy and toxicity of MTX were evaluated through clinical follow-up during 1 year of treatment. RA patients showed a higher frequency of the T allele at MTHFR C677T than patients without RA (p=0.049). There was a significant association between the presence of both the T allele at MTHFR C677T (p=0.006), and the C allele at ABCB1 C3435T (p=0.046), with toxicity development after 12 months of MTX treatment. However, there was no correlation between MTX toxicity and either the A allele at MTHFR A1298C or the G allele at RFC1 A80G. These data suggest that the presence of the MTHFR C677T and ABCB1 C3435T SNPs contribute to MTX toxicity in patients with RA. These observations contribute to a rapidly-growing knowledge base on the pharmacogenetics of RA and personalized medicine.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results